武汉肚子痛排便排血一般是什么原因武汉屁眼为什么会痛,武汉肚子疼快速止痛方法,武汉大便用力肛门出血,武汉每天放好多屁是怎么回事,武汉拉大便出血怎么治,武汉肛门有几个肉球出来但是不疼,武汉正常的肛门褶皱图片和痔疮图片

WASHINGTON, Oct. 9 (Xinhua) -- U.S. researchers have found a way to block, in an animal model, the damaging inflammation that contributes to many disease conditions. In their report receiving early online publication Sunday in Nature Biotechnology, researchers describe using small interfering RNA technology to silence the biochemical signals that attract a particular group of inflammatory cells to areas of tissue damage."The white blood cells known as monocytes play a critical role in the early stages of the immune response," says Matthias Nahrendorf, of the Massachusetts General Hospital (MGH) Center for Systems Biology, the paper's senior author. "We now know there are two subsets of monocytes -- an inflammatory subset that defends against pathogens and a reparative subset that supports healing. But if the inflammatory response is excessive, it can block the healing process and exacerbate conditions such as heart disease and cancer."Cells damaged by injury or disease release a cocktail of chemicals called cytokines that attract immune cells to the site of the damage. Inflammatory monocytes are guided to sites of tissue injury by a receptor protein called CCR2, and the MGH-led team devised a strategy targeting that molecule to block the inflammatory process but not the action of the reparative monocytes.Small interfering RNA (siRNA) technology prevents production of specific proteins by binding to associated messenger RNA molecules and preventing their translation. However, the technique requires extreme precision in developing the right siRNA molecule and delivering it to the correct cellular location.To make sure that their siRNA preparation targeted the right monocytes, researchers first confirmed that its use reduced levels of CCR2 in monocytes and increased levels of the fragments produced when siRNA binds to its target. They then showed that monocytes from mice treated with the siRNA preparation were unable to migrate towards CCR2's usual molecular target. Experiments in animal models of several important diseases showed that the siRNA preparation reduced the amount of cardiac muscle damaged by a heart attack, reduced the size and the number of inflammatory cells in atherosclerotic plaques and in lymphomas, and improved the survival of transplanted pancreatic islets."These inflammatory monocytes are involved in almost every major disease," Nahrendorf explains. "Anti-inflammatory drugs currently on the market hit every inflammatory cell in the body, which can produce unwanted side effects. This new siRNA treatment doesn't affect inflammatory cells that don't rely on the CCR2 receptor. That makes a big difference."

WASHINGTON, Jan. 19 (Xinhua) -- New research published this week in Nature Medicine indicates that targeted drugs such as gefitinib might more effectively treat non-small cell lung cancer if they could be combined with agents that block certain microRNAs.The study, led by investigators with the Ohio State University Comprehensive Cancer Center, shows that overexpression of two genes called MET and EGFR causes the deregulation of six microRNAs, and that this deregulation leads to gefitinib resistance.The findings support the development of agents that restore the levels of these microRNAs. It offers a new strategy for treating non-small cell lung cancer, which is responsible for about 85 percent of the 221,000 lung-cancer cases and 157,000 deaths that occur annually in the United States. It also suggests that measuring the expression levels of certain microRNAs -- those controlled by the MET gene -- might predict which lung-cancer cases are likely to be resistant to gefitinib.Epidermal growth factor receptor (EGFR) is frequently overexpressed in non-small cell lung cancer, and this leads to uncontrolled cell proliferation. Gefitinib selectively inhibits EGFR activation and triggers cancer cells to self-destruct by apoptosis. However, non-small cell lung cancer cells inevitably develop resistance to the drug. The study reveals how this resistance occurs."Our findings suggest that gefitinib resistance that is caused by MET overexpression is at least partly due to miRNA deregulation, " says principal investigator Carlo Croce.

ATHENS, Nov. 11 (Xinhua) -- The third Forum on the Development of Tibet concluded here on Friday after discussions on efforts to promote the world's understanding of Tibet and enhance the cooperation between China and the rest of the world with regards to Tibet's development.This year marks the 60th anniversary of Tibet's peaceful liberation. During the two-day event, delegates from Greece, Britain, France, Germany, India and Nepal expressed their opinions on Tibet's modernization and put forward valuable advice and suggestions based on their own experience and research findings.Some of the foreign delegates have visited Tibet many times before. Narasimhan Ram, Editor-in-chief of The Hindu from India and Brendan O'Neill, editor of the British magazine Spiked spoke positively about the preferential polices and financial support of the Chinese central government and other parts of China for the region.During the Forum, Wang Chen, head of the Chinese State Council Information Office met with the Greek political leaders and journalists from mainstream media.People got an opportunity to learn more about China as Nyima Tsering, Vice Chairman of the Standing Committee of the People's Congress of the Tibet Autonomous Region, introduced the development of Tibet and the Chinese government's policy towards the region.A number of Greek mainstream media covered the Forum.Over the past 60 years, Tibet has achieved a huge development in both its social structure and socio-economic development, said a communique released upon the end of the forum.It also foresees a great potential of cooperation with the international community in energy, environment, education and healthcare development for the region.The forum has facilitated better understanding of Tibet in the international community and will help to promote faster and better development of the autonomous region, the Communique said.

SAN FRANCISCO, Oct. 17 (Xinhua) -- Apple on Monday announced that it has sold more than four million of its new iPhone 4S, three days after the launch last Friday."IPhone 4S is off to a great start with more than four million sold in its first weekend--the most ever for a phone and more than double the iPhone 4 launch during its first three days," said Philip Schiller, Apple's senior vice president of worldwide product marketing.In addition, more than 25 million customers are already using iOS 5, the latest version of the mobile operating system powering Apple's mobile devices, since it was released last Wednesday; and more than 20 million customers have signed up for iCloud, the cloud service designed to store and sync data for download to multiple devices, said the company in the statement.The iPhone 4S, which looks the same as the iPhone 4, has major hardware upgrade inside, including a faster chip, a higher- resolution camera and Siri intelligent voice control.Last Friday, AT&T and Sprint, two iPhone wireless carriers in the United States, said they have seen record daily sales with the launch of the iPhone 4S.The lasted Apple smartphone is currently on sale in the U.S., Canada, France, Germany, Japan and Britain, and will be available in 22 more countries on Oct. 28. Apple said the phone will be on sale in more than 70 countries and regions by the end of this year.

LOS ANGELES, Dec. 21 (Xinhua) -- The late Apple co-founder Steve Jobs will be honored posthumously with a Grammy award for his contributions to music technology, The Recording Academy announced on Wednesday.Jobs, who passed away Oct. 5 of pancreatic cancer, will receive a Trustees Award for helping create products "that transformed the way we consume music, TV, movies and books," the academy said in a prepared statement.The Apple Computer Inc. first received a Technical Grammy Award in 2002, for contributions of outstanding technical significance to the recording field, the academy said.Along with Jobs, bandleader and composer Dave Bartholomew, recording engineer Rudy Van Gelder will also receive the award.The academy also picked the Allman Brothers, Glen Campbell, Diana Ross and Brazilian pianist/singer/guitarist Antonio Carlos Jobim as recipients of Lifetime Achievement Awards. Jobim was known for composing "The Girl from Ipanema," a worldwide hit in the mid-1960s which won a Grammy for Record of the Year in 1965.Other artists, including trumpeter Wayne Jackson, saxophonist Andrew Love of the Memphis Horns,country legend George Jones,and the late Gil Scott-Heron were also named as recipients.German sound-technology firm Celemony and the late audio engineer Roger Nichols, who worked with artists including Ross, Placido Domingo, James Taylor and Stevie Wonder, were recognized with Grammy Technical Awards."This year's honorees offer a variety of brilliance, contributions and lasting impressions on our culture," said President/CEO of The Recording Academy Neil Portnow. "It is an honor to recognize such a diverse group of individuals whose talents and achievements have had an indelible impact on our industry."The honorees will be formally acknowledged during the 54th Annual Grammy Awards telecast at Staples Center in downtown Los Angeles on Feb. 12, 2012.